论文部分内容阅读
目的探讨栓塞微球应用于肝动脉化疗栓塞(TACE)治疗乏血供肝癌的临床疗效。方法选取2011年6月至2013年12月间无锡市第五人民医院收治的60例原发性肝癌患者,采用随机数表法分为研究组与对照组,每组30例。研究组患者采用栓塞微球为栓塞剂,对照组以碘化油加明胶海绵为栓塞剂,患者均至少经过两次肝动脉化疗栓塞术后,比较两组患者肿瘤病灶近期变化、不良反应及生存时间。结果术后研究组患者肝功能损害指标谷丙转氨酶(ALT)值高于对照组患者,差异有统计学意义(P<0.05)。研究组患者和对照组患者的总有效率分别为40.0%和20.0%,疾病控制率分别为93.3%和70.0%,差异有统计学意义(P<0.05)。研究组患者18个月生存率优于对照组患者,研究组患者和对照组患者中位生存时间分别为11个月和8个月,差异均有统计学意义(均P<0.05)。结论以栓塞微球为栓塞剂的肝动脉化疗栓塞对乏血供肝癌具有一定的疗效,值得临床进一步研究。
Objective To investigate the clinical efficacy of embolization microspheres in the treatment of hepatic arterial chemoembolization (TACE) in patients with hematopoietic failure. Methods A total of 60 patients with primary liver cancer who were admitted to the Fifth People’s Hospital of Wuxi from June 2011 to December 2013 were randomly divided into study group and control group, with 30 cases in each group. In the study group, embolism microspheres were used as embolization agents. In the control group, iodized oil and gelatin sponge were used as embolization agents. After undergoing at least two hepatic arterial chemoembolizations, the recent changes in the tumor focus, adverse reactions, and survival were compared between the two groups. time. Results The serum ALT levels in the postoperative group were significantly higher than those in the control group (P<0.05). The total effective rates of the study group and the control group were 40.0% and 20.0%, respectively, and the disease control rates were 93.3% and 70.0%, respectively. The difference was statistically significant (P<0.05). The 18-month survival rate of the study group was better than that of the control group. The median survival time of the study group and the control group was 11 months and 8 months respectively, and the differences were statistically significant (all P<0.05). Conclusion Transcatheter arterial chemoembolization using embolization microspheres as an embolization agent has a certain effect on the lack of blood supply to liver cancer and is worthy of further clinical research.